GlassScriptPhysician profile
Ali Safdar
NPI 1043211303
$3,822.94
in general payments reported to CMS, 2019-2025
23 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $514 · 2021: $744 · 2022: $447 · 2023: $344 · 2024: $320 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $815.36 | 2019-2020 | |
| Abbvie INC. | $461.46 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $455.25 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $413.69 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $390.91 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.23 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $182.34 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $171.44 | 2019-2021 | |
| Lundbeck LLC | $159.54 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $133.37 | 2021-2025 | Fanapt |
| Indivior INC. | $90.44 | 2022-2023 | Perseris |
| Almatica Pharma LLC | $61.03 | 2022-2024 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $46.00 | 2019-2025 | Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $43.71 | 2022-2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $38.19 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $35.73 | 2022-2024 | |
| Ironshore Pharmaceuticals INC. | $33.18 | 2024 | |
| Pfizer INC. | $25.66 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.94 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $14.88 | 2023 | Belsomra |
| Corium, LLC | $14.73 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.93 | 2025 | Jornay Pm |
| Shire North American Group INC | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Safdar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.